A serious infection after an endoscopy does not by itself prove that the scope caused the infection. The first useful question is more specific: what procedure was performed, which Olympus device or accessory was used, when did symptoms begin, and what did the culture and treatment records show?

That model-by-model approach is especially important in 2026. Olympus makes many reusable endoscopic devices, but the current FDA record does not treat every scope, accessory, or procedure as the same problem. Palmer Law is reviewing serious infection and device-injury matters after Olympus endoscopic procedures, with the exact device identity and medical timeline serving as the starting point.

Start with the procedure and the model number, not the word “endoscopy”

Palmer Law reviews matters involving procedures ranging from ERCP and upper endoscopy to colonoscopy, bronchoscopy, cystoscopy, ureteroscopy, hysteroscopy, laparoscopy, and sinus endoscopy. Those procedures do not all use the same device, and they should not be collapsed into one assumption about defect or contamination.

The strongest current federal regulatory evidence concerns particular Olympus devices and accessories. For example, FDA recall records for the EVIS EXERA III TJF-Q190V duodenovideoscope describe continued reports of positive cultures and infections and updated reprocessing materials. Separate 2026 FDA records concern a redesigned single-use distal cover used with that scope. That is much more precise than saying every Olympus scope has the same cleaning problem.

Why reprocessing matters in a scope-infection investigation

Reusable endoscopes must be cleaned and disinfected between patients. FDA explains that duodenoscopes are complex instruments with small working parts and that tissue or fluid can remain if a device is not thoroughly reprocessed. In rare cases, that can contribute to patient-to-patient transmission of infection.

The current regulatory history also shows why the reprocessing timeline matters. A 2025 FDA recall for the Olympus TJF-Q190V cited post-market data suggesting higher microbial contamination when manual cleaning was delayed beyond one hour under certain circumstances. A later 2025 correction, classified in the 2026 recall cycle, cited continued reports of positive cultures and infections and updated reprocessing materials.

Those records do not establish causation in any particular patient. They do identify concrete device and cleaning issues that can guide a records-based investigation.

Olympus also has a documented federal reporting history

In 2018, Olympus Medical Systems Corporation pleaded guilty in federal court to distributing misbranded endoscopes after failing to file required FDA adverse-event reports involving serious infections connected to an earlier duodenoscope model. The Justice Department said the company paid an $80 million fine and $5 million in criminal forfeiture and agreed to compliance reforms.

That historical plea is relevant context, but it is not automatic proof that a current device was defective or that a particular infection was caused by an Olympus scope. The history helps explain why device identification and reporting records matter, but it does not replace the need to evaluate individual medical causation.

The evidence trail is often more important than the symptom list

A person may know only that an infection appeared after a procedure. The records can answer much more. The procedure report may identify the type of scope or accessory. The facility may have device logs or serial-number records. Laboratory reports can identify the organism. Hospital records can show when symptoms began, whether sepsis developed, what antibiotics were used, and whether the infection was drug-resistant.

The patient usually does not need to obtain a hospital’s internal reprocessing logs before asking for a legal review. The useful first step is to preserve what is already available and identify the facility, procedure date, and doctors involved so counsel can determine what additional evidence may exist.

What to gather before an Olympus scope review

  • The endoscopy, colonoscopy, ERCP, bronchoscopy, or other procedure report.
  • The facility name and exact date of the procedure.
  • Any document identifying the Olympus model, serial number, accessory, or device used.
  • Culture and microbiology reports identifying the organism, if known.
  • Hospitalization, infectious-disease, antibiotic, surgery, or intensive-care records connected to the complication.
  • A simple timeline showing when symptoms began after the procedure and what treatment followed.

Palmer’s current screening criteria

Palmer Law currently reviews serious infections, device-related injuries, and procedure-related complications after endoscopic procedures from 2018 forward. The firm’s current screening criteria also reference hospitalization within 90 days and certain drug-resistant infections within 180 days.

Those time windows are Palmer screening criteria, not medical rules proving that a scope caused an infection. The legal analysis still depends on the device, the procedure, the organism or injury, the chronology, and the applicable law. A person whose symptoms appeared outside a screening window can still request an individual review of the facts.

Why an individual Olympus scope review matters

An infection after an endoscopic procedure does not automatically mean Olympus is responsible, and not every Olympus device has been recalled for the same reason. The existence of a recall, correction, or prior regulatory action also does not by itself establish that a particular device caused a particular injury.

Serious post-procedure infections and device injuries can warrant a product-liability review, but the claim begins with identifying the exact product and medical evidence.

Request an Olympus scope case review

If you or a family member developed a serious infection or device-related injury after an endoscopic procedure involving an Olympus product, Palmer Law can begin by reviewing the procedure, timing, diagnosis, treatment, and available device information. Palmer can then explain whether the matter fits the firm’s current case criteria and, if appropriate, whether the firm can assist directly or coordinate with trusted legal counsel.